<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03425565</url>
  </required_header>
  <id_info>
    <org_study_id>UCL/17/0672</org_study_id>
    <nct_id>NCT03425565</nct_id>
  </id_info>
  <brief_title>A Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancer</brief_title>
  <acronym>PEACOCC</acronym>
  <official_title>A Phase II Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PEACOCC is a multi-centre, single arm, single stage phase II trial. The overall aim is to&#xD;
      determine whether treatment with pembrolizumab is effective in patients with advanced clear&#xD;
      cell gynaecological cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 18, 2019</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Clear Cell Tumor</condition>
  <condition>Gynecologic Cancer</condition>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>3 weekly cycles of Pembrolizumab administered by IV</description>
    <arm_group_label>Pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          1. Histological diagnosis of advanced clear cell ovarian (including primary peritoneal&#xD;
             and fallopian tube), endometrial, vaginal, vulval or cervical cancer.&#xD;
&#xD;
          2. Have measurable disease based on RECIST 1.1.&#xD;
&#xD;
          3. Evidence of radiological disease progression.&#xD;
&#xD;
          4. Patient is willing to provide tissue from a newly obtained core or excisional biopsy&#xD;
             of a tumour lesion at baseline, 6-8 weeks after start of treatment and at the time of&#xD;
             progression.&#xD;
&#xD;
          5. ECOG Performance Status 0 or 1.&#xD;
&#xD;
          6. Patient has a life expectancy of at least 3 months from consent.&#xD;
&#xD;
          7. Received â‰¥ 1 line of prior chemotherapy .&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          1. Has a known diagnosis of immunodeficiency or is receiving systemic steroid therapy at&#xD;
             doses &gt; 10mg prednisolone daily or equivalent or any other form of immunosuppressive&#xD;
             therapy within 7 days prior to the first dose of trial treatment.&#xD;
&#xD;
          2. Has a known history of active TB (Bacillus Tuberculosis), Hepatitis B (e.g., HBsAg&#xD;
             reactive), Hepatitis C or a known history of Human Immunodeficiency Virus (HIV).&#xD;
&#xD;
          3. Has symptomatic central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis.&#xD;
&#xD;
          4. Has active autoimmune disease that has required systemic treatment in the past 2 years&#xD;
             (i.e. with use of disease modifying agents, corticosteroids (at a dose &gt;10mg&#xD;
             predisolone daily or equivalent) or immunosuppressive drugs).&#xD;
&#xD;
          5. Has known history or evidence of active, non-infectious pneumonitis.&#xD;
&#xD;
          6. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.&#xD;
&#xD;
          7. Has received a live vaccine within 30 days prior to the planned start of trial&#xD;
             treatment.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Hospital</name>
      <address>
        <city>Northwood</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 1, 2018</study_first_submitted>
  <study_first_submitted_qc>February 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2018</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

